INT223565

Context Info Confidence 0.01 First Reported 2007 Last Reported 2007 Negated 0 Speculated 0 Reported most in Body Documents 1 Total Number 5 Disease Relevance 1.07 Pain Relevance 0.27

Anatomy Link Frequency blood vessels 3 bladders 1 lymphatic vessels 1 cy (Mus musculus)

Pain Link Frequency Relevance Heat imagery 215 95.72 Inflammation 25 56.80 isoflurane 10 5.00 anesthesia 5 5.00

Disease Link Frequency Relevance Heat Bladder Cancer 160 92.00 Cancer 245 73.28 Targeted Disruption 65 71.48 INFLAMMATION 25 56.80 Stress Incontinence 10 50.24 Metastasis 30 5.00 Transitional Cell Carcinoma 15 5.00 Peripheral Arterial Disease 10 5.00 Reprotox - General 1 10 5.00 Lymphatic Metastasis 10 5.00

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

Co-localization of Cy5.5 with LYVE-1 positive lymphatics and CD31-positive blood vessels

Localization (localization) of Cy5 in blood vessels

1) Confidence 0.01 Published 2007 Journal BMC Cancer Section Body Doc Link PMC2241841 Disease Relevance 0.05 Pain Relevance 0

In terms of co-localization of Cy5.5, at 120 minutes, Cy5.5 was found evenly distributed between LYVE-1-positive lymphatics and CD31-positive blood vessels (Figure 9).

Localization (localization) of Cy5 in blood vessels

2) Confidence 0.01 Published 2007 Journal BMC Cancer Section Body Doc Link PMC2241841 Disease Relevance 0 Pain Relevance 0.04

The yellow label indicates co-localization of Cy5.5 with CD31-positive blood vessels, or LYVE-1-positive lymphatic vessels.

Localization (localization) of Cy5 in lymphatic vessels

3) Confidence 0.01 Published 2007 Journal BMC Cancer Section Body Doc Link PMC2241841 Disease Relevance 0 Pain Relevance 0

To confirm the results obtained in vivo, groups of mice (n = 3) were euthanized at 2, 5.5, and 24 hours (120, 330, and 1440 minutes) after i.v. administration of Gd-Cy5.5 and the bladders were removed for analysis of co-localization of Cy5.5 with LYVE-1- and CD31-positive cells.

Localization (localization) of Cy5 in bladders

4) Confidence 0.01 Published 2007 Journal BMC Cancer Section Body Doc Link PMC2241841 Disease Relevance 0 Pain Relevance 0

In addition, IHC of Cy5.5 was used for time-course analysis of co-localization of Gd-Cy5.5 with LYVE-1-positive lymphatics and CD31-positive blood vessels.

Localization (localization) of Cy5 in blood vessels

5) Confidence 0.01 Published 2007 Journal BMC Cancer Section Abstract Doc Link PMC2241841 Disease Relevance 1.02 Pain Relevance 0.23

General Comments

This test has worked.